[go: up one dir, main page]

AR072336A1 - Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion - Google Patents

Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion

Info

Publication number
AR072336A1
AR072336A1 ARP080105365A ARP080105365A AR072336A1 AR 072336 A1 AR072336 A1 AR 072336A1 AR P080105365 A ARP080105365 A AR P080105365A AR P080105365 A ARP080105365 A AR P080105365A AR 072336 A1 AR072336 A1 AR 072336A1
Authority
AR
Argentina
Prior art keywords
alkyl
compound
formula
independently
procedure
Prior art date
Application number
ARP080105365A
Other languages
English (en)
Inventor
John R Jacobsen
Miroslav Rapta
Sean G Trapp
Michael R Leadbetter
Priscilla M Vandyke
Pierre-Jean Colson
Daniel D Long
Ying Yu
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR072336A1 publication Critical patent/AR072336A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1), caracterizado porque R1 es -ORa o -C(O)NRbRc; R2, R3 y R4 son, cada uno en forma independiente, alquilo C1-3; R5 se selecciona de alquilo C1-6, fenilo, ciclohexilo, -(CH2)1-3-ciclohexilo y -(CH2)1-3-fenilo; Ra, Rb y Rc son, cada uno en forma independiente, hidrogeno o alquilo C1-3; y R6 es hidrogeno o alquilo C1-3; y porque los sustituyentes en los centros quirales marcados con asteriscos se presentan en la configuracion trans; o una de sus sales farmacéuticamente aceptables. Reivindicacion 13: Una composicion farmacéutica que comprende el compuesto de cualquiera de las reivindicaciones 1 a 12 y un portador farmacéuticamente aceptable. Reivindicacion 15: Un procedimiento para elaborar un compuesto de la formula (1), o una de sus sales, caracterizado porque R1 es -ORa o -C(O)NRbRc; R2, R3 y R4 son, cada uno en forma independiente, alquilo C1-3; R5 se selecciona de alquilo C1-6, fenilo, ciclohexilo, -(CH2)1-3-ciclohexilo y -(CH2)1-3-fenilo; Ra, Rb y Rc son, cada uno en forma independiente, hidrogeno o alquilo C1-3; y R6 es hidrogeno o alquilo C1-3; y porque los sustituyentes en los centros quirales marcados con asteriscos se presentan en la configuracion trans; el procedimiento comprende: (a) hacer reaccionar un compuesto de la formula (2) con un compuesto de la formula (3), caracterizado porque R6 es alquilo C1-3; y (b) cuando R6 es hidrogeno, poner en contacto el producto del paso (a) con un exceso de base para proporcionar un compuesto de formula (1) o una de sus sales. Reivindicacion 16: Un compuesto de formula (4) o una de sus sales de bromhidrato, caracterizado porque R2 y R3 son, cada uno en forma independiente, alquilo C1-3, y los sustituyentes en los centros quirales marcados con asteriscos están en la configuracion trans. Reivindicacion 17: Un procedimiento para elaborar una sal de bromhidrato de un compuesto de la formula (4) en forma solida, caracterizado porque R2 y R3 son, cada uno en forma independiente, alquilo C1-3, y los sustituyentes en los centros quirales marcados con asteriscos se presentan en la configuracion trans; el procedimiento comprende: (a) hacer reaccionar una mezcla racémica de un compuesto de formula (5) y un compuesto que tiene la estereoquímica opuesta en los centros quirales, donde P1 es alquilo C1-3, con bromuro de hidrogeno para formar la sal de bromhidrato del compuesto de formula (4); y (b) aislar la sal de bromhidrato del compuesto de la formula (4) en forma solida.
ARP080105365A 2007-12-11 2008-12-10 Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion AR072336A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US722007P 2007-12-11 2007-12-11
US4921908P 2008-04-30 2008-04-30

Publications (1)

Publication Number Publication Date
AR072336A1 true AR072336A1 (es) 2010-08-25

Family

ID=40521484

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105365A AR072336A1 (es) 2007-12-11 2008-12-10 Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion

Country Status (18)

Country Link
US (5) US8106232B2 (es)
EP (1) EP2231585B1 (es)
JP (1) JP5403762B2 (es)
KR (1) KR101610165B1 (es)
CN (1) CN101896455B (es)
AR (1) AR072336A1 (es)
AU (1) AU2008335210B2 (es)
BR (1) BRPI0821611A8 (es)
CA (1) CA2707981C (es)
CL (1) CL2008003672A1 (es)
CO (1) CO6300937A2 (es)
ES (1) ES2402749T3 (es)
IL (1) IL205949A (es)
MY (1) MY149973A (es)
NZ (1) NZ586048A (es)
RU (1) RU2482107C2 (es)
TW (1) TWI412360B (es)
WO (1) WO2009076408A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
AR069039A1 (es) 2007-10-26 2009-12-23 Univ California Compuestos de diarilhidantoina, composicion farmaceutica, proceso de obtencion del compuesto, utiles para desordenes hiperproliferativos
WO2009076399A2 (en) 2007-12-11 2009-06-18 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists
US8153686B2 (en) 2008-04-01 2012-04-10 Theravance, Inc. Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
WO2010068649A1 (en) 2008-12-10 2010-06-17 Theravance, Inc. Crystalline forms of a 3-carboxypropyl-aminotetralin compound
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
US6498196B1 (en) * 1998-12-22 2002-12-24 Edward Roberts Compounds useful in pain management
US6844368B1 (en) 1998-12-22 2005-01-18 Edward Roberts Compounds useful in pain management
WO2000037426A1 (en) * 1998-12-22 2000-06-29 Astrazeneca Ab Novel oxo-aminotetralin compounds useful in pain management
AU3092800A (en) * 1998-12-22 2000-07-12 Astra Pharma Inc. Novel thio-aminotetralin compounds useful in pain management
US6231594B1 (en) * 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
EP2097083A2 (en) 2006-11-07 2009-09-09 Nektar Therapeutics AL, Corporation Dosage forms and co-administration of an opioid agonist and an opioid antagonist
WO2009076399A2 (en) 2007-12-11 2009-06-18 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists
US8153686B2 (en) 2008-04-01 2012-04-10 Theravance, Inc. Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
WO2010068649A1 (en) 2008-12-10 2010-06-17 Theravance, Inc. Crystalline forms of a 3-carboxypropyl-aminotetralin compound

Also Published As

Publication number Publication date
KR20100100939A (ko) 2010-09-15
US20140031380A1 (en) 2014-01-30
IL205949A (en) 2014-03-31
WO2009076408A2 (en) 2009-06-18
CA2707981A1 (en) 2009-06-18
US8106232B2 (en) 2012-01-31
US8318765B2 (en) 2012-11-27
EP2231585B1 (en) 2013-02-13
TW200932211A (en) 2009-08-01
BRPI0821611A8 (pt) 2016-12-13
KR101610165B1 (ko) 2016-04-08
AU2008335210A1 (en) 2009-06-18
MY149973A (en) 2013-11-15
WO2009076408A3 (en) 2009-09-03
EP2231585A2 (en) 2010-09-29
US20130035510A1 (en) 2013-02-07
JP2011506463A (ja) 2011-03-03
US20120088787A1 (en) 2012-04-12
BRPI0821611A2 (pt) 2015-08-25
CL2008003672A1 (es) 2009-05-29
RU2482107C2 (ru) 2013-05-20
CO6300937A2 (es) 2011-07-21
NZ586048A (en) 2012-06-29
RU2010128542A (ru) 2012-01-27
JP5403762B2 (ja) 2014-01-29
CA2707981C (en) 2016-05-10
AU2008335210B2 (en) 2013-10-10
US20090149535A1 (en) 2009-06-11
US20140329845A1 (en) 2014-11-06
US8492399B2 (en) 2013-07-23
CN101896455B (zh) 2015-04-29
IL205949A0 (en) 2010-11-30
CN101896455A (zh) 2010-11-24
US8969370B2 (en) 2015-03-03
ES2402749T3 (es) 2013-05-08
TWI412360B (zh) 2013-10-21
US8703791B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
AR072336A1 (es) Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion
AR046938A1 (es) Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR064730A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
MX2018000592A (es) Derivados de etinilo como moduladores del receptor de glutamato metabotropico.
AR068056A1 (es) Derivados de n, n'-2, 4 - dianilinopirimidinas, su preparacion, su uso como medicamentos, composiciones farmaceuticas y especialmente como inhibidores de ikk.
AR044829A1 (es) Derivados de bis-4-cloro fenil pirazinas
AR004972A1 (es) Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado.
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
BRPI0308696B8 (pt) composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
AR059085A1 (es) Derivados azufrados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de quinasas
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
ES2531396T3 (es) Proceso para preparar compuestos de piridinona
AR059086A1 (es) Derivados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de cinasas
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
EA201490722A1 (ru) ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR068467A1 (es) Compuestos de nicotinamida sustituida y sus usos en medicamentos
MY165141A (en) Pyrazolidin-3-one derivatives
AR075160A1 (es) Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
AR072118A1 (es) Derivados de pirrolidina como antagonistas de receptor de nk2
AR062941A1 (es) Compuestos para el tratamiento de desordenes metabolicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure